Co-deletion of chromosome 1p/19q and IDH1/2 mutation in glioma subsets of brain tumors in Chinese patients

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Ren, Xiaohui ^a   Cui, Xiangli ^a   Lin, Song ^a   Wang, Junmei ^b   Jiang, Zhongli ^a   Sui, Dali ^a   Li, Jing ^a   Wang, Zhongcheng ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ASTROCYTOMA; BRAIN REGION; CANCER GRADING; CHINESE; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FRONTAL LOBE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC CORRELATION; GLIOMA; HEMISPHERIC DOMINANCE; HUMAN; IDH1 GENE; IDH2 GENE; INSULA; MAJOR CLINICAL STUDY; MALE; MARKER GENE; OLIGODENDROGLIOMA; PREDICTIVE VALUE; PROGNOSIS; REVIEW; TEMPORAL LOBE; TUMOR LOCALIZATION; ARTICLE; ASIAN; BRAIN TUMOR; CHROMOSOME 1; DNA SEQUENCE; GENETICS; MIDDLE AGED; MUTATION;

IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; PRIMER DNA;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; DNA PRIMERS; GENETIC ASSOCIATION STUDIES; GLIOMA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; ISOCITRATE DEHYDROGENASE; MIDDLE AGED; MUTATION; SEQUENCE ANALYSIS, DNA;

EID: 84863251079     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032764     Document Type: Review

References (30)

1. Ohgaki H, Kleihues P, (2005) Epidemiology and etiology of gliomas. Acta Neuropathol 109: 93-108.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109.
3. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M, (2006) Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2: 494-503, 1-516.
4. Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, et al. (1995) Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 54: 91-95.
5. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, et al. (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24: 2715-2722.
6. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, et al. (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24: 2707-2714.
7. Kros JM, Gorlia T, Kouwenhoven MC, Zheng PP, Collins VP, et al. (2007) Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 66: 545-551.
8. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, et al. (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90: 1473-1479.
9. Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, et al. (2007) Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68: 1831-1836.
10. Kujas M, Lejeune J, Benouaich-Amiel A, Criniere E, Laigle-Donadey F, et al. (2005) Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas. Ann Neurol 58: 322-326.
11. Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, et al. (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22: 3133-3138.
12. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, et al. (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66: 9852-9861.
13. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
14. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H, (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174: 1149-1153.
15. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, et al. (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27: 4150-4154.
16. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.
17. Bleeker FE, Atai NA, Lamba S, Jonker A, Rijkeboer D, et al. (2010) The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol 119: 487-494.
18. Larjavaara S, Mantyla R, Salminen T, Haapasalo H, Raitanen J, et al. (2007) Incidence of gliomas by anatomic location. Neuro Oncol 9: 319-325.
19. Duffau H, Capelle L, (2004) Preferential brain locations of low-grade gliomas. Cancer 100: 2622-2626.
20. Zlatescu MC, TehraniYazdi A, Sasaki H, Megyesi JF, Betensky RA, et al. (2001) Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 61: 6713-6715.
21. Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, et al. (2002) Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 161: 313-319.
22. Huang L, Jiang T, Yuan F, Li GL, Liu EZ, et al. (2008) Correlations between molecular profile and tumor location in Chinese patients with oligodendroglial tumors. Clin Neurol Neurosurg 110: 1020-1024.
23. Goze C, Rigau V, Gibert L, Maudelonde T, Duffau H, (2009) Lack of complete 1p19q deletion in a consecutive series of 12 WHO grade II gliomas involving the insula: a marker of worse prognosis? J Neurooncol 91: 1-5.
24. Wu A, Aldape K, Lang FF, (2010) High rate of deletion of chromosomes 1p and 19q in insular oligodendroglial tumors. J Neurooncol 99: 57-64.
25. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, et al. (2011) Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29: 4482-4490.
26. Ambros PF, Ambros IM, (2001) Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 37: 492-504.
27. Yasargil MG, Reeves JD, (1992) Tumours of the limbic and paralimbic system. Acta Neurochir (Wien) 116: 147-149.
28. Sanai N, Polley MY, Berger MS, (2010) Insular glioma resection: assessment of patient morbidity, survival, and tumor progression. J Neurosurg 112: 1-9.
29. Lang FF, Olansen NE, DeMonte F, Gokaslan ZL, Holland EC, et al. (2001) Surgical resection of intrinsic insular tumors: complication avoidance. J Neurosurg 95: 638-650.
30. Laigle-Donadey F, Martin-Duverneuil N, Lejeune J, Criniere E, Capelle L, et al. (2004) Correlations between molecular profile and radiologic pattern in oligodendroglial tumors. Neurology 63: 2360-2362.